+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Ophthalmic Drugs Market by Product Type (Over-The-Counter Drugs, Prescription Drugs), Drug Class (Anti-Allergics, Anti-Glaucoma Agents, Anti-Inflammatories), Dosage Form, Route of Administration, Therapeutic Area, Patient Demographics, End User - Global Forecast 2025-2030- Product Image
Ophthalmic Drugs Market by Product Type (Over-The-Counter Drugs, Prescription Drugs), Drug Class (Anti-Allergics, Anti-Glaucoma Agents, Anti-Inflammatories), Dosage Form, Route of Administration, Therapeutic Area, Patient Demographics, End User - Global Forecast 2025-2030- Product Image
Sale

Ophthalmic Drugs Market by Product Type (Over-The-Counter Drugs, Prescription Drugs), Drug Class (Anti-Allergics, Anti-Glaucoma Agents, Anti-Inflammatories), Dosage Form, Route of Administration, Therapeutic Area, Patient Demographics, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 180 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968753
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Ophthalmic Drugs Market grew from USD 41.56 billion in 2024 to USD 44.47 billion in 2025. It is expected to continue growing at a CAGR of 7.30%, reaching USD 63.44 billion by 2030.

The ophthalmic drugs market is experiencing a period of profound transformation driven by innovative research, evolving patient needs, and rapid regulatory updates. This executive summary provides an extensive overview of current market dynamics and lays the foundation for understanding the factors that are reshaping the industry. In today’s competitive pharmaceutical environment, stakeholders are focused on bridging the gap between cutting‐edge scientific breakthroughs and effective, accessible therapies. Pharmaceutical companies, healthcare providers, and investors alike are navigating an increasingly complex regulatory framework while striving to meet the challenge of treating a broad range of ocular conditions.

This report offers an integrated perspective on market segmentation, regional trends, key players, and actionable recommendations that can empower industry leaders. It emphasizes the importance of aligning product innovation with shifting consumer demographics and therapeutic demands. By understanding the forces at play, stakeholders can capitalize on emerging opportunities and mitigate risks. The discussion also highlights the advancement in drug formulations and the role of digital technologies in influencing market access and patient engagement. Overall, this comprehensive introduction sets the stage for a deeper dive into the nuanced strategies and segmentation insights that define the ever-evolving landscape of ophthalmic pharmaceuticals.

Transformative Shifts in the Ophthalmic Drugs Landscape

Over recent years, the ophthalmic drugs market has witnessed dramatic shifts that are redefining industry trajectories. Developments in pharmacological research paired with evolving patient expectations have contributed to a more agile landscape. Companies are investing heavily in research and development to fast-track innovative therapeutics that address both common and complex ocular conditions. Regulatory agencies, too, have embraced streamlined approval processes for breakthrough drugs, which in turn fuels market dynamism.

The surge in digital health solutions has amplified the reach of ophthalmological services. Telemedicine tools and remote diagnostic technologies have become indispensable in connecting patients with specialized care, ensuring timely interventions and enhanced patient adherence. Stakeholders are increasingly leveraging integrated data analytics to predict trends and customize treatment strategies that meet the personalized needs of different population segments. In parallel, mergers and strategic collaborations have intensified, driving consolidation, technological synergies, and broader distribution networks. These transformative shifts are propelling the market into a new phase where innovation, patient-centricity, and operational agility form the backbone of competitive success.

Key Segmentation Insights Across Multiple Market Dimensions

Segmenting the ophthalmic drugs market offers valuable insights into the diverse treatment options and therapeutic approaches available today. When analyzed by product type, the market is categorized into over-the-counter drugs and prescription drugs, each addressing varying degrees of ocular conditions based on severity and regulatory requirements. Delving into drug classes reveals a wealth of therapeutic options, including anti-allergics, anti-glaucoma agents, anti-inflammatories, antibiotics, antifungals, antivirals, and combination drugs. Notably, anti-inflammatories are further studied by distinguishing non-steroidal anti-inflammatories from steroidal counterparts, reflecting nuances in pharmacodynamic activity and safety profiles. Similarly, the antibiotic class is carefully segmented into groups such as aminoglycosides, fluoroquinolones, macrolides, and tetracyclines, which underscores the precision required in targeting ocular infections.

Analysis by dosage form encompasses eye drops, gels, ointments, and tablets & capsules, each offering distinct delivery mechanisms and patient compliance advantages. Further segmentation based on the route of administration - injectable, oral, and topical - highlights the diverse modalities used to optimize drug absorption. The therapeutic area segmentation covers conditions such as cataracts, conjunctivitis, dry eye syndrome, glaucoma, ocular infections, and retinal disorders; within conjunctivitis, the differentiation into allergic, bacterial, and viral subtypes illustrates the tailored approaches needed for effective treatment. Patient demographics, ranging from adult to geriatric and pediatric segments, demand flexible dosing regimens and safety profiles, while end user analysis spans hospitals, online pharmacies, ophthalmic clinics, and retail pharmacies & drug stores, each with unique market dynamics and distribution challenges.

Based on Product Type, market is studied across Over-The-Counter Drugs and Prescription Drugs.

Based on Drug Class, market is studied across Anti-Allergics, Anti-Glaucoma Agents, Anti-Inflammatories, Antibiotics, Antifungal, Antiviral, and Combination Drugs. The Anti-Inflammatories is further studied across Non-Steroidal Anti-Inflammatories and Steroidal Anti-Inflammatories. The Antibiotics is further studied across Aminoglycosides, Fluoroquinolones, Macrolides, and Tetracyclines.

Based on Dosage Form, market is studied across Eye Drops, Gels, Ointments, and Tablets & Capsules.

Based on Route of Administration, market is studied across Injectable, Oral, and Topical.

Based on Therapeutic Area, market is studied across Cataracts, Conjunctivitis, Dry Eye Syndrome, Glaucoma, Ocular Infections, and Retinal Disorders. The Conjunctivitis is further studied across Allergic Conjunctivitis, Bacterial Conjunctivitis, and Viral Conjunctivitis.

Based on Patient Demographics, market is studied across Adult, Geriatric, and Pediatric.

Based on End User, market is studied across Hospitals, Online Pharmacies, Ophthalmic Clinics, and Retail Pharmacies & Drug Stores.

Key Regional Insights Shaping the Global Market

Examining the regional landscape reveals distinct market characteristics that are reshaping the ophthalmic drugs industry globally. In the Americas, a robust healthcare infrastructure coupled with high investment in biotechnology and pharmaceuticals has driven substantial growth. This region benefits from state-of-the-art clinical practices, strong regulatory mechanisms, and a surge in technological integration, all of which contribute to a dynamic market environment.

Turn attention to regions spanning Europe, the Middle East, and Africa, where market evolution is influenced by diverse economic conditions and varying levels of healthcare access. These regions are witnessing a blend of traditional treatment modalities with emerging innovative therapies, resulting in a complex competitive landscape. Rigorous regulatory reforms and strategic public-private partnerships further stimulate market expansion in these diverse territories. Asia-Pacific has emerged as a significant growth engine, powered by rapid urbanization, rising disposable incomes, and increasing demand for advanced medical solutions. As healthcare infrastructure continues to improve in this region, stakeholders are fast adapting to local market needs and patient preferences. Together, these regions highlight the varied yet interconnected trends that underscore the global momentum of the ophthalmic drugs market.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Driving Innovation and Market Leadership

The competitive landscape of the ophthalmic drugs market is defined by the strategic initiatives of numerous prominent industry players. Companies such as Abbott Laboratories and Alcon Vision LLC are at the forefront, consistently introducing innovative products that address unmet clinical needs. Renowned pharmaceutical giants like Allergan PLC by AbbVie Inc., Apotex Inc., and Bausch Health Companies Inc. have established robust pipelines that leverage advanced drug delivery systems and targeted therapeutic profiles.

Leaders including Bayer AG, Carl Zeiss AG, and EyePoint Pharmaceuticals, Inc. have further strengthened their market positions through significant investments in research and technological development. Genentech, Inc. and Johnson & Johnson Service, Inc. continue to drive forward-thinking solutions with a focus on both product efficacy and patient safety. Up-and-coming innovators like Kodiak Sciences Inc. and Lotus Pharmaceutical Co., Ltd. are disrupting the market with niche therapies that respond to evolving patient demographics. Additionally, companies such as Lupin Limited, Merck & Co., Nicox SA, and Novartis AG are recognized for their commitment to quality and comprehensive portfolio strategies. Ocular Therapeutix, Inc., OCuSOFT Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co.,Ltd., Somerset Pharma, LLC., Sun Pharmaceutical Industries, Inc., Takeda Pharmaceutical Company Limited, and Viatris Inc. round out a list of key players who are relentlessly pursuing excellence in ophthalmic care, setting benchmarks in both clinical innovation and market penetration.

The report delves into recent significant developments in the Ophthalmic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alcon Vision LLC, Allergan PLC by AbbVie Inc., Apotex Inc., Bausch Health Companies Inc., Bayer AG, Carl Zeiss AG, EyePoint Pharmaceuticals, Inc., Genentech, Inc., Johnson & Johnson Service, Inc., Kodiak Sciences Inc., Lotus Pharmaceutical Co., Ltd., Lupin Limited, Merck & Co., Nicox SA, Novartis AG, Ocular Therapeutix, Inc., OCuSOFT Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co.,Ltd., Somerset Pharma, LLC., Sun Pharmaceutical Industries, Inc., Takeda Pharmaceutical Company Limited, and Viatris Inc..

Actionable Recommendations for Future Market Excellence

Industry leaders are encouraged to take decisive, informed actions to leverage growth opportunities in the ophthalmic drugs market. It is essential to remain agile and invest in the latest innovations by prioritizing research and development. Companies should periodically assess their product portfolios to ensure that both over-the-counter and prescription drugs align with emerging trends and patient expectations. Emphasis on diversifying drug classes, such as optimizing anti-inflammatory and antibiotic segments, can provide competitive differentiation based on specialized therapeutic needs.

Furthermore, aligning product formulations with the appropriate dosage forms and routes of administration is critical for enhancing patient adherence and clinical outcomes. Expanding market reach by understanding demographic shifts - from adult to pediatric and geriatric segments - and tailoring strategies to meet these distinct demands will foster long-term growth. Strategic collaborations and technology partnerships can also accelerate digital transformation, facilitate regulatory compliance, and enhance distribution channels across hospitals, online pharmacies, and retail environments. A proactive approach in these areas, supported by robust data analytics and market intelligence, will help navigate uncertainties and secure a leading edge in a competitive global market.

Summarizing the Strategic Insights

In conclusion, the ophthalmic drugs market is undergoing significant changes fueled by innovations in therapeutic product development, enhanced diagnostic tools, and evolving patient needs. The segmentation analysis, spanning product type, drug class, dosage form, route of administration, therapeutic area, patient demographics, and end use, underscores the complexity and richness of the market landscape. Regional examinations further reveal that while the Americas continue to lead in infrastructure and investment, the combined forces of Europe, the Middle East & Africa, and Asia-Pacific are charting new growth trajectories through collaborative ventures and technology-driven healthcare solutions.

The competitive positioning of key industry players and strategic recommendations underscore the necessity for forward-thinking leadership. Embracing digital advances, optimizing product portfolios, and fostering synergies across market segments are crucial for navigating emerging challenges. Ultimately, the report reinforces the importance of continuous innovation and strategic agility in ensuring sustainable growth and competitive differentiation in the ophthalmic drugs sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing awareness and accessibility to eye care services
5.1.1.2. Increasing prevalence of eye disorders and vision impairment
5.1.2. Restraints
5.1.2.1. Significant concerns over product recall issues
5.1.3. Opportunities
5.1.3.1. Development of personalized medicine in ophthalmology
5.1.3.2. Expansion of healthcare infrastructure across the globe
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements for drug approvals
5.2. Market Segmentation Analysis
5.2.1. Drug Class: Burgeoning usages of anti-allergics cater to the growing prevalence of allergic conjunctivitis
5.2.2. End User: Expanding usage of the ophthalmic clinics prioritizing premium and targeted therapeutic solutions
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Ophthalmic Drugs Market, by Product Type
6.1. Introduction
6.2. Over-The-Counter Drugs
6.3. Prescription Drugs
7. Ophthalmic Drugs Market, by Drug Class
7.1. Introduction
7.2. Anti-Allergics
7.3. Anti-Glaucoma Agents
7.4. Anti-Inflammatories
7.4.1. Non-Steroidal Anti-Inflammatories
7.4.2. Steroidal Anti-Inflammatories
7.5. Antibiotics
7.5.1. Aminoglycosides
7.5.2. Fluoroquinolones
7.5.3. Macrolides
7.5.4. Tetracyclines
7.6. Antifungal
7.7. Antiviral
7.8. Combination Drugs
8. Ophthalmic Drugs Market, by Dosage Form
8.1. Introduction
8.2. Eye Drops
8.3. Gels
8.4. Ointments
8.5. Tablets & Capsules
9. Ophthalmic Drugs Market, by Route of Administration
9.1. Introduction
9.2. Injectable
9.3. Oral
9.4. Topical
10. Ophthalmic Drugs Market, by Therapeutic Area
10.1. Introduction
10.2. Cataracts
10.3. Conjunctivitis
10.3.1. Allergic Conjunctivitis
10.3.2. Bacterial Conjunctivitis
10.3.3. Viral Conjunctivitis
10.4. Dry Eye Syndrome
10.5. Glaucoma
10.6. Ocular Infections
10.7. Retinal Disorders
11. Ophthalmic Drugs Market, by Patient Demographics
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Ophthalmic Drugs Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Online Pharmacies
12.4. Ophthalmic Clinics
12.5. Retail Pharmacies & Drug Stores
13. Americas Ophthalmic Drugs Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Ophthalmic Drugs Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Ophthalmic Drugs Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Scenario Analysis
16.3.1. Glenmark Pharmaceuticals expands its US market presence with the launch of Travoprost ophthalmic solution for treating glaucoma and ocular hypertension
16.3.2. Eyenovia's launch of clobetasol propionate heralds a new era in post-surgical ophthalmic care
16.3.3. Entod Pharmaceuticals introduces PresVu eye drops in India as a non-surgical solution for presbyopia
16.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. OPHTHALMIC DRUGS MARKET MULTI-CURRENCY
FIGURE 2. OPHTHALMIC DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. OPHTHALMIC DRUGS MARKET RESEARCH PROCESS
FIGURE 4. OPHTHALMIC DRUGS MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 9. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 11. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 13. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 15. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 17. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 19. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 21. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 23. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 24. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 25. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 26. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 27. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 30. OPHTHALMIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 31. OPHTHALMIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. OPHTHALMIC DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. OPHTHALMIC DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY STEROIDAL ANTI-INFLAMMATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ANTIFUNGAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY TABLETS & CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY CATARACTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ALLERGIC CONJUNCTIVITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY BACTERIAL CONJUNCTIVITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY VIRAL CONJUNCTIVITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRY EYE SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY OCULAR INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 87. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 89. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 90. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 91. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 93. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 94. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 95. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 97. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 99. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 101. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 103. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 104. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 105. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 120. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 122. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 124. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 126. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 128. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 129. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 131. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 132. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 133. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 135. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 136. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 137. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 139. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 141. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 142. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 143. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 145. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 146. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 147. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 149. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 151. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 152. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 153. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 155. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 156. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 157. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 159. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 161. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 162. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 163. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 165. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 166. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 167. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 169. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 171. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 172. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 173. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 175. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 176. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 177. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 179. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 181. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 182. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 183. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 185. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 186. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 187. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 189. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 191. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 192. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 193. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 195. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 196. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 197. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 199. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 200. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 201. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 202. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 203. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 205. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 206. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 207. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 209. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 210. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 211. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 212. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 213. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 215. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 216. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 217. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 219. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 220. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 221. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 222. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 223. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 225. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 226. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 227. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 229. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 230. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 231. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 232. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 233. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 235. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 236. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 237. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 239. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 240. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 241. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 242. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 243. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 245. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 246. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 247. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 259. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 260. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 261. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 262. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 263. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 264. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 266. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 267. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 268. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 270. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 271. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 272. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 273. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 274. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 276. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 277. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 278. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 280. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 281. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 282. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 283. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 284. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 286. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 287. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 288. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 290. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 291. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 292. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 293. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 294. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 295. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 296. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 297. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 298. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 300. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 301. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 302. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 303. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 304. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 305. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 306. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 307. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 308. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 310. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 311. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 312. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 313. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 316. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 317. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 318. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 319. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 320. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 321. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 322. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 323. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 324. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 325. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 326. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 327. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 328. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 329. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 330. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 331. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 332. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 333. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 334. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 335. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 336. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 337. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 338. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 339. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 340. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 341. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 342. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 343. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 344. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 345. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 346. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 347. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 348. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 349. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 3

Companies Mentioned

  • Abbott Laboratories
  • Alcon Vision LLC
  • Allergan PLC by AbbVie Inc.
  • Apotex Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Carl Zeiss AG
  • EyePoint Pharmaceuticals, Inc.
  • Genentech, Inc.
  • Johnson & Johnson Service, Inc.
  • Kodiak Sciences Inc.
  • Lotus Pharmaceutical Co., Ltd.
  • Lupin Limited
  • Merck & Co.
  • Nicox SA
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • OCuSOFT Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Senju Pharmaceutical Co.,Ltd.
  • Somerset Pharma, LLC.
  • Sun Pharmaceutical Industries, Inc.
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages180
PublishedMarch 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 44.47 Billion
Forecasted Market Value ( USD ) by 2030 $ 63.44 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Ophthalmic Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Ophthalmic Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Ophthalmic Drugs Market Report by Type, Drug Class, Indication, Dosage Form, Distribution Channel, and Region 2024-2032 - Product Image

Ophthalmic Drugs Market Report by Type, Drug Class, Indication, Dosage Form, Distribution Channel, and Region 2024-2032

  • Report
  • 136 Pages
  • Global
From
Ophthalmic Drug Delivery Systems Market Size, Share & Trends Analysis Report By Technology (Eye Drops, Contact Lenses), By Delivery Route, By Production Technology, By Material, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Ophthalmic Drug Delivery Systems Market Size, Share & Trends Analysis Report By Technology (Eye Drops, Contact Lenses), By Delivery Route, By Production Technology, By Material, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 190 Pages
  • Global
From
Ophthalmic Drug Delivery System Market by Drug Type, Delivery Device Type, Product Type, Formulation Type, Mode of Delivery, Application, End User - Global Forecast 2025-2030 - Product Image

Ophthalmic Drug Delivery System Market by Drug Type, Delivery Device Type, Product Type, Formulation Type, Mode of Delivery, Application, End User - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Ophthalmic Drugs Market Report 2025-2035 - Product Image

Ophthalmic Drugs Market Report 2025-2035

  • Report
  • 340 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.